Standard Operating Procedure for SOP Review and Control in Elixir Manufacturing

1. Purpose

To define the procedure for the creation, review, approval, distribution, revision, retrieval, and archival of Standard Operating Procedures (SOPs) to ensure consistent practices and regulatory compliance across the Elixir Department.

2. Scope

This SOP applies to all SOPs that govern the activities in manufacturing, quality control, quality assurance, engineering, and warehouse operations within the Elixir Department.

3. Responsibilities

• Document Originator:
  • Drafts the SOP using approved templates and initiates revisions when required.
• QA Documentation Cell:
  • Controls SOP numbering, distribution, archival, and ensures implementation.
• Department Head:
  • Reviews and approves department-specific SOPs for accuracy and relevance.

4. Accountability

The Head of Quality Assurance is accountable for the compliance and effectiveness of the SOP review and control process.

5. Procedure

5.1 SOP Preparation

1. Use the approved SOP template from QA which includes:
   • Title, SOP number, purpose, scope, responsibilities, procedure, version, revision history
2. Each SOP must be assigned a unique SOP number (e.g., SOP/ELX/XXX/YYYY).

5.2 SOP Review

1. All SOPs must be reviewed at least once every two years or sooner if:
   • There are regulatory changes
   • There are process changes or equipment upgrades
   • Deviation or audit findings require revision
2. QA initiates a review by notifying the respective department.

5.3 SOP Approval

1. After review, the SOP is signed by:
   • Prepared by – Originator
   • Checked by – Department Head
   • Approved by – QA Head
2. Approval signatures must be dated and documented in the approval section.

5.4 SOP Issuance and Distribution

1. QA issues controlled copies of the approved SOP to relevant departments.
2. A copy control record is maintained (Annexure-1: SOP Distribution Record).

5.5 SOP Revision

1. Revisions must be initiated through a change control or scheduled review.
2. Revised SOPs must include:
   • New version number
   • Reason for change in the revision history
   • Superseded SOP retrieval

5.6 SOP Archival and Retrieval

1. Obsolete SOPs must be stamped “Obsolete” and archived for at least 5 years.
2. Retrieval of old SOPs for audits or investigations must be approved by QA.

6. Abbreviations

• SOP: Standard Operating Procedure
• QA: Quality Assurance
• cGMP: Current Good Manufacturing Practices

7. Documents

1. SOP Distribution Record (Annexure-1)
2. SOP Master List (Annexure-2)
3. Change Control Request (if applicable)

8. References

• ICH Q10 – Pharmaceutical Quality System
• WHO TRS 986 – Annex 2 GMP Guidelines
• 21 CFR Part 211.100 – Written Procedures

9. SOP Version

Version: 2.0

10. Approval Section

11. Annexures

Annexure-1: SOP Distribution Record

Annexure-2: SOP Master List

Revision History:

Standard Operating Procedure for Vendor Qualification for Raw Materials in Elixir Manufacturing

1. Purpose

To establish a formal procedure for evaluating, qualifying, monitoring, and approving vendors supplying raw materials (APIs, excipients, solvents, etc.) used in elixir manufacturing to ensure consistent material quality and regulatory compliance.

2. Scope

This SOP applies to the qualification of all vendors supplying raw materials for use in the Elixir Department, including initial qualification, requalification, and disqualification processes.

3. Responsibilities

• Purchase Department:
  • Initiate vendor selection and send qualification questionnaire.
• Quality Assurance (QA):
  • Coordinate vendor audits, maintain vendor files, and approve qualification status.
• Quality Control (QC):
  • Evaluate material quality and provide analytical feedback.

4. Accountability

The Head of QA is accountable for ensuring that vendors are qualified and monitored in accordance with this SOP and regulatory standards.

5. Procedure

5.1 Vendor Selection

1. Purchase department identifies potential vendor based on:
   • GMP compliance
   • Geographical reliability
   • Business reputation
2. Send Vendor Qualification Questionnaire (Annexure-1).

5.2 Vendor Evaluation

1. QA reviews questionnaire for:
   • Manufacturing site licenses
   • Quality systems in place
   • CoAs and test methods used
   • Regulatory approvals (e.g., WHO, FDA, etc.)
2. Evaluate at least 3 commercial lots of material before provisional approval.

5.3 Vendor Audit

1. QA shall schedule and conduct on-site audits for high-risk or critical vendors (APIs, solvents).
2. Audit checklist (Annexure-2) must cover:
   • Facility and equipment hygiene
   • Documentation and data integrity
   • Process controls
3. Audit report with CAPA (if any) to be submitted within 10 working days of audit.

5.4 Approval and Listing

1. QA reviews audit and analytical evaluation outcomes.
2. If satisfactory, add vendor to Approved Vendor List (Annexure-3).
3. Assign vendor status: Approved, Conditionally Approved, or Rejected.

5.5 Requalification and Monitoring

1. Conduct requalification every 2 years or after any major quality issue.
2. Monitor vendor performance using:
   • Rejection trends
   • OOS/OOT results
   • Customer complaints (if applicable)

5.6 Disqualification

1. QA may disqualify a vendor based on:
   • Repeated quality failures
   • Unresolved audit observations
   • Breach of GMP compliance
2. Document disqualification reason and notify the purchase department.

6. Abbreviations

• SOP: Standard Operating Procedure
• QA: Quality Assurance
• QC: Quality Control
• CoA: Certificate of Analysis
• OOS: Out of Specification
• CAPA: Corrective and Preventive Action

7. Documents

1. Vendor Qualification Questionnaire (Annexure-1)
2. Vendor Audit Checklist (Annexure-2)
3. Approved Vendor List (Annexure-3)

8. References

• ICH Q7 – Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients
• WHO TRS 1010 – GMP for Pharmaceutical Products
• 21 CFR Part 211 – cGMP for Finished Pharmaceuticals

9. SOP Version

Version: 2.0

10. Approval Section

11. Annexures

Annexure-1: Vendor Qualification Questionnaire

Annexure-2: Vendor Audit Checklist

Annexure-3: Approved Vendor List

Revision History:

Standard Operating Procedure for Product Release Authorization in Elixir Manufacturing

1. Purpose

To define the procedure for authorizing the release of finished elixir products after completion of manufacturing, testing, and batch documentation review, in accordance with cGMP and regulatory requirements.

2. Scope

This SOP applies to all commercial and validation batches of elixirs manufactured and tested within the facility and intended for release to the market or further processing.

3. Responsibilities

• Production Officer:
  • Ensure batch manufacturing record (BMR) is completed and submitted to QA.
• QC Analyst:
  • Complete all required analytical testing and submit results to QA.
• QA Reviewer:
  • Review batch records, QC data, and ensure compliance before batch release.

4. Accountability

The Head of Quality Assurance is accountable for final authorization and release of the product batch. The Head of Production is responsible for compliance with manufacturing and documentation practices.

5. Procedure

5.1 Batch Documentation Review

1. QA shall receive the complete BMR and associated records from production.
2. Verify the following:
   • Batch number, product name, strength, pack size
   • Line clearance entries
   • Manufacturing process steps, signatures, and timestamps
   • Yield reconciliation and deviations (if any)

5.2 Review of QC Analytical Results

1. Confirm all raw materials, in-process samples, and finished product results meet specifications.
2. Review chromatograms, microbial test reports, alcohol content, viscosity, clarity, and pH results.
3. Ensure OOS or OOT results are resolved and approved by QA prior to release.

5.3 Final Release Decision

1. After complete review, QA shall fill the Product Release Authorization Form (Annexure-1).
2. Product can only be released after QA Head’s signature and date of authorization.
3. Released batches shall be recorded in the Batch Release Register (Annexure-2).

5.4 Retention and Traceability

1. All batch-related documents must be archived securely and be traceable for audits.
2. Electronic or manual logs must be updated upon release.

6. Abbreviations

• SOP: Standard Operating Procedure
• BMR: Batch Manufacturing Record
• QA: Quality Assurance
• QC: Quality Control
• OOS: Out of Specification
• OOT: Out of Trend

7. Documents

1. Product Release Authorization Form (Annexure-1)
2. Batch Release Register (Annexure-2)
3. Analytical Test Reports

8. References

• 21 CFR Part 211.165 – Testing and Release for Distribution
• ICH Q10 – Pharmaceutical Quality System
• WHO GMP Guidelines

9. SOP Version

Version: 2.0

10. Approval Section

11. Annexures

Annexure-1: Product Release Authorization Form

Annexure-2: Batch Release Register

Revision History:

Standard Operating Procedure for Review of Analytical Data in Elixir Manufacturing

1. Purpose

To establish a standardized procedure for the review of analytical data generated during testing of raw materials, in-process samples, and finished elixir products to ensure completeness, accuracy, and compliance with cGMP and data integrity standards.

2. Scope

This SOP is applicable to all Quality Control (QC) personnel and Quality Assurance (QA) reviewers involved in the generation, review, approval, and archival of analytical data within the Elixir Department.

3. Responsibilities

• QC Analyst:
  • Ensure data is recorded contemporaneously, completely, and accurately in accordance with approved procedures.
• QC Reviewer:
  • Perform first-level review of analytical results, raw data, calculations, and instrument printouts.
• QA Reviewer:
  • Conduct second-level review, verify compliance with specifications and approve results for release.

4. Accountability

The Head of Quality Control is accountable for ensuring adherence to this SOP. The Head of Quality Assurance is responsible for ensuring regulatory compliance and integrity of analytical data.

5. Procedure

5.1 General Requirements

1. All analytical data shall be recorded in indelible ink or electronically using validated systems.
2. Data must be attributable, legible, contemporaneous, original, accurate (ALCOA+).
3. Each page shall be signed and dated by the person performing the activity.

5.2 QC First-Level Review

1. Check that all test parameters have been recorded and calculated correctly.
2. Verify:
   • Instrument calibration status on the date of analysis
   • Standard preparation records and validity
   • Chromatograms, spectrums, or reports generated
   • Labels on samples and reagents used
3. Confirm entries match those in the test request and batch documents.

5.3 QA Second-Level Review

1. Ensure that the QC review is completed and compliant.
2. Verify critical test results (e.g., assay, dissolution, alcohol content) against specifications.
3. Ensure OOS, OOT, or deviations are documented and investigated.
4. Sign and date the analytical worksheet and stamp it “Approved” or “Rejected”.

5.4 Electronic Data Review

1. Review audit trails for electronic systems (HPLC, UV, IR, etc.) to verify no unauthorized changes.
2. Ensure electronic records are securely stored and backed up per data integrity policies.

5.5 Archival of Analytical Data

1. After approval, all original data must be filed in the Analytical Data File specific to each batch.
2. Electronic data must be archived in validated and access-controlled systems.
3. Retention period: Minimum 1 year after product expiry or as per local regulations.

6. Abbreviations

• SOP: Standard Operating Procedure
• QC: Quality Control
• QA: Quality Assurance
• OOS: Out of Specification
• OOT: Out of Trend
• ALCOA+: Attributable, Legible, Contemporaneous, Original, Accurate, Complete, Consistent, Enduring, and Available

7. Documents

1. Analytical Data Review Checklist (Annexure-1)
2. Approved Specification Sheet
3. Test Request and Batch Record

8. References

• 21 CFR Part 211.194 – Laboratory Records
• ICH Q7 – Good Manufacturing Practice for Active Pharmaceutical Ingredients
• MHRA GxP Data Integrity Guidance

9. SOP Version

Version: 2.0

10. Approval Section

11. Annexures

Annexure-1: Analytical Data Review Checklist

Revision History:

Standard Operating Procedure for Documentation Control in Elixir Manufacturing

1. Purpose

To establish a systematic approach for the preparation, approval, issuance, revision, retrieval, archival, and destruction of GMP-related documents used in elixir manufacturing to ensure accuracy, consistency, traceability, and regulatory compliance.

2. Scope

This SOP applies to all controlled documents within the Elixir Department, including SOPs, batch manufacturing records (BMR), forms, logs, protocols, reports, and any other GMP-critical documentation.

3. Responsibilities

• Document Originator:
  • Draft and revise documents as per standard format.
• QA Documentation Cell:
  • Assign document numbers, control issuance, maintain the document master list, and retrieve obsolete documents.
• Department Head:
  • Review and approve department-specific documents and ensure implementation.

4. Accountability

The QA Head is accountable for the implementation and compliance of the documentation control procedure across the Elixir Department.

5. Procedure

5.1 Document Types

• SOPs (Standard Operating Procedures)
• Protocols (e.g., validation, qualification)
• Reports (e.g., validation, deviation, investigation)
• Records (e.g., BMRs, logbooks, forms)
• Master documents (e.g., MFR, MPCR, specifications)

5.2 Document Numbering System

1. Each document will have a unique identifier (e.g., SOP/ELX/XXX/YYYY) where:
   • XXX = serial number
   • YYYY = year of issue
2. QA shall maintain a Document Master Index (Annexure-1).

5.3 Document Preparation

1. Use standard templates provided by QA.
2. Include all required sections such as title, purpose, scope, procedure, responsibilities, version, and revision history.
3. Drafted documents are reviewed by the Department Head and submitted to QA for approval.

5.4 Document Issuance and Control

1. QA issues controlled copies with a red “Controlled Copy” stamp and serial number.
2. Uncontrolled copies (e.g., for training) are marked “Uncontrolled Copy – For Reference Only”.
3. Obsolete documents are removed from circulation and replaced with updated versions.

5.5 Document Revision

1. Revisions are initiated when:
   • Regulatory guidelines change
   • Process/equipment changes
   • Periodic review identifies gaps
2. Each revision must be reflected in the “Revision History” section.

5.6 Document Archival and Retention

1. All obsolete and completed records must be archived in a secure, access-controlled environment.
2. Retention period:
   • Batch records: 1 year after expiry
   • SOPs and logs: Minimum of 5 years

5.7 Document Destruction

1. Expired records are destroyed under QA supervision with documented approval.
2. Record destruction must be entered in the Document Disposal Register (Annexure-2).

6. Abbreviations

• SOP: Standard Operating Procedure
• QA: Quality Assurance
• BMR: Batch Manufacturing Record
• MFR: Master Formula Record

7. Documents

1. Document Master Index (Annexure-1)
2. Document Disposal Register (Annexure-2)
3. Document Revision Log

8. References

• 21 CFR Part 211.180 – General Requirements
• WHO GMP Guidelines for Pharmaceuticals
• ICH Q10 – Pharmaceutical Quality System

9. SOP Version

Version: 2.0

10. Approval Section

11. Annexures

Annexure-1: Document Master Index

Annexure-2: Document Disposal Register

Revision History:

Standard Operating Procedure for Risk Assessment During Elixir Manufacturing

1. Purpose

To define the procedure for performing structured and systematic risk assessments during the manufacturing of elixir products to proactively identify, evaluate, and control potential risks that may impact product quality, safety, or compliance.

2. Scope

This SOP applies to all risk assessments conducted during process development, batch manufacturing, equipment operation, cleaning, and deviations in the Elixir Department.

3. Responsibilities

• Manufacturing Officer:
  • Identify and report potential risks observed during operations.
• QA Officer:
  • Facilitate risk assessment sessions, ensure proper documentation, and evaluate mitigation strategies.
• Department Head:
  • Approve implementation of control measures and follow-up actions.

4. Accountability

The QA Head is accountable for ensuring that all risk assessments are conducted, documented, and reviewed as per regulatory guidelines (ICH Q9).

5. Procedure

5.1 Risk Assessment Tools

Use one or more of the following tools depending on the nature of the risk:

• FMEA (Failure Modes and Effects Analysis)
• Fishbone Diagram (Ishikawa)
• 5 Whys Technique
• Risk Ranking and Filtering

5.2 Risk Assessment Initiation

1. Initiated when:
   • New process/equipment is introduced
   • Critical deviation occurs
   • Change control is raised
   • Periodic review identifies gaps
2. QA issues Risk Assessment Form (Annexure-1) and assigns a unique Risk ID.

5.3 Risk Identification

1. Cross-functional team identifies failure modes or hazards related to:
   • Personnel
   • Materials
   • Methods
   • Machines
   • Environment
2. List all potential failure points across the manufacturing process flow.

5.4 Risk Evaluation

1. Use Risk Priority Number (RPN) = Severity × Occurrence × Detectability.
2. Rate each parameter on a scale of 1 (Low) to 5 (High).
3. Classify overall risk as:
   • Low (RPN 1–25)
   • Medium (RPN 26–50)
   • High (RPN 51–75)

5.5 Risk Control

1. For Medium to High risks, propose and document control measures such as:
   • SOP revision
   • Additional training
   • Equipment calibration/maintenance
   • Process validation
2. Re-calculate RPN post mitigation to assess effectiveness.

5.6 Documentation and Review

1. Complete the Risk Assessment Report and attach supporting evidence.
2. Submit to QA for review and closure approval.
3. Include finalized risk reports in Product Quality Review (PQR) annually.

6. Abbreviations

• SOP: Standard Operating Procedure
• FMEA: Failure Modes and Effects Analysis
• RPN: Risk Priority Number
• QA: Quality Assurance

7. Documents

1. Risk Assessment Form (Annexure-1)
2. Risk Register (Annexure-2)
3. CAPA Form (if required)

8. References

• ICH Q9 – Quality Risk Management
• 21 CFR Part 211 – cGMP for Finished Pharmaceuticals
• WHO Technical Report Series No. 986, Annex 2

9. SOP Version

Version: 2.0

10. Approval Section

11. Annexures

Annexure-1: Risk Assessment Form

Annexure-2: Risk Register

Revision History:

Standard Operating Procedure for Change Control Procedure in Elixir Manufacturing

1. Purpose

To define a formal system for initiating, evaluating, approving, implementing, and reviewing changes that may impact the quality, safety, or efficacy of elixir products and associated processes in compliance with cGMP and regulatory expectations.

2. Scope

This SOP applies to all proposed changes related to facilities, utilities, equipment, materials, documents, processes, test methods, and computer systems involved in elixir manufacturing, testing, and distribution.

3. Responsibilities

• Initiator (Any Department):
  • Identify the need for change and fill out the Change Control Request Form (Annexure-1).
• Department Head:
  • Perform initial assessment of proposed change and submit for QA review.
• QA Officer:
  • Assign change control number, perform risk assessment, and coordinate cross-functional review.
• Change Control Committee (CCC):
  • Evaluate and approve/reject major changes after full impact assessment.

4. Accountability

The QA Head is accountable for maintaining the change control system, ensuring timely execution, documentation, and regulatory compliance.

5. Procedure

5.1 Types of Change

• Minor Change: Change with minimal impact, e.g., equipment ID renumbering, editorial document corrections.
• Major Change: Change with potential regulatory, product quality, or validation impact, e.g., formulation modification, facility layout redesign, vendor replacement.

5.2 Change Request Initiation

1. The initiator fills the Change Control Request Form (Annexure-1) and submits it to QA.
2. QA assigns a unique Change Control Number (e.g., CC/ELX/2025/001) and logs in Change Control Register (Annexure-2).

5.3 Impact Assessment

1. QA coordinates with affected departments (Production, QC, Engineering, Regulatory, IT) to perform impact assessment.
2. Evaluate impact on:
   • Product quality and safety
   • GMP compliance
   • Validation status
   • Regulatory filings
   • Training and documentation

5.4 Approval

1. Minor changes may be approved by QA and department head.
2. Major changes must be reviewed by the Change Control Committee (CCC) and require QA Head approval.

5.5 Implementation

1. Assigned teams execute the change as per action plan and timelines.
2. Update impacted SOPs, protocols, validation documents, and train concerned personnel.

5.6 Verification and Closure

1. QA verifies implementation and supporting documents.
2. Post-change review is conducted to confirm intended outcomes.
3. QA signs off the closure section of Change Control Form.

5.7 Change Control Metrics

1. QA shall review monthly open and closed changes, and include data in quality metrics.
2. Delayed closures must be escalated with justification to senior QA.

6. Abbreviations

• SOP: Standard Operating Procedure
• QA: Quality Assurance
• CCC: Change Control Committee
• GMP: Good Manufacturing Practice

7. Documents

1. Change Control Request Form (Annexure-1)
2. Change Control Register (Annexure-2)
3. Risk Assessment Worksheet

8. References

• ICH Q10 – Pharmaceutical Quality System
• 21 CFR Part 211.100 – Written Procedures and Change Control
• WHO Technical Report Series No. 986 – Annex 2

9. SOP Version

Version: 2.0

10. Approval Section

11. Annexures

Annexure-1: Change Control Request Form

Annexure-2: Change Control Register

Revision History:

Standard Operating Procedure for Deviation Management in Elixir Manufacturing

1. Purpose

To define the process for identification, documentation, investigation, evaluation, and closure of deviations occurring during the manufacturing, testing, storage, or handling of elixir products in compliance with cGMP.

2. Scope

This SOP is applicable to all planned and unplanned deviations observed in the Elixir Department across production, quality control, warehouse, and engineering operations.

3. Responsibilities

• All Department Personnel:
  • Report any deviation observed during routine operations.
• Department Head:
  • Ensure timely documentation and preliminary impact assessment.
• QA Officer:
  • Initiate deviation number, coordinate investigation, and ensure timely closure.

4. Accountability

The QA Head is accountable for ensuring compliance with this SOP and regulatory expectations related to deviation investigation and control.

5. Procedure

5.1 Types of Deviations

• Planned Deviation: A deviation pre-approved by QA for a temporary and controlled change.
• Unplanned Deviation: Any unexpected incident or non-compliance with approved procedures or parameters.

5.2 Identification and Documentation

1. Any deviation observed must be reported immediately to the department supervisor and QA.
2. QA shall issue a unique deviation number and deviation form (Annexure-1).
3. The concerned department must fill in:
   • Date and time of deviation
   • Brief description
   • Batch/product details (if applicable)
   • Initial impact assessment

5.3 Investigation and Impact Analysis

1. QA along with department head shall initiate an investigation.
2. Determine root cause using tools like:
   • Fishbone diagram
   • 5 Whys technique
3. Assess potential impact on:
   • Product quality
   • Patient safety
   • Regulatory compliance

5.4 Corrective and Preventive Action (CAPA)

1. Propose suitable CAPA based on root cause analysis.
2. Assign responsible persons and timelines for CAPA execution.
3. QA shall verify CAPA implementation and effectiveness.

5.5 Deviation Closure

1. Once investigation and CAPA are complete, QA shall:
   • Review deviation file
   • Approve closure with remarks
2. Deviation shall be closed within 30 working days from initiation unless extended with justification.

5.6 Trending and Review

1. QA shall maintain a Deviation Register (Annexure-2) and trend deviations monthly.
2. Include deviation trends in Product Quality Review (PQR).

6. Abbreviations

• SOP: Standard Operating Procedure
• QA: Quality Assurance
• CAPA: Corrective and Preventive Action
• cGMP: Current Good Manufacturing Practices

7. Documents

1. Deviation Report Form (Annexure-1)
2. Deviation Register (Annexure-2)
3. Root Cause Analysis Record

8. References

• 21 CFR Part 211.100 – Written Procedures; Deviations
• ICH Q10 – Pharmaceutical Quality System
• WHO TRS 986 Annex 2 – GMP for Pharmaceutical Products

9. SOP Version

Version: 2.0

10. Approval Section

11. Annexures

Annexure-1: Deviation Report Form

Annexure-2: Deviation Register

Revision History:

Standard Operating Procedure for Line Clearance Before and After Elixir Manufacturing

1. Purpose

To define the procedure for conducting line clearance before starting and after completing elixir manufacturing operations in order to prevent mix-ups, cross-contamination, and ensure equipment and area readiness.

2. Scope

This SOP applies to all manufacturing lines and equipment used in the production of elixirs, including weighing, mixing, filtration, and holding areas in the Elixir Department.

3. Responsibilities

• Manufacturing Officer:
  • Ensure cleaning of area and equipment is completed.
  • Request line clearance prior to and after batch execution.
• IPQA Officer:
  • Perform physical verification of the line clearance checkpoints.
  • Document clearance in the Line Clearance Checklist.
• Production Supervisor:
  • Ensure rectification of discrepancies and overall readiness of the line.

4. Accountability

The Head of Production is accountable for execution of the procedure. The Head of QA is responsible for compliance to cGMP and data integrity during line clearance checks.

5. Procedure

5.1 Line Clearance Before Manufacturing

1. Verify the area and equipment cleaning status and completion of cleaning logs.
2. Ensure previous batch documents, materials, labels, and samples are removed.
3. Check that:
   • Equipment status labels reflect “Cleaned and Ready for Use”.
   • Material containers are properly labeled with batch number and name.
   • Weighing balances are calibrated and verified.
   • Product-specific utensils are cleaned and identified.
4. Complete the Line Clearance Checklist (Annexure-1).
5. QA/ IPQA shall authorize line clearance before batch execution starts.

5.2 Line Clearance After Manufacturing

1. Ensure product transfer to the next stage (e.g., filtration or storage) is complete.
2. Confirm that no material, labels, or batch documents from the completed batch are left behind.
3. Check that:
   • Equipment is properly cleaned and visually inspected.
   • Spillage or powder residues are cleaned from surfaces and floors.
   • Environmental conditions (temperature/humidity) are within limits.
4. Document observations and complete post-manufacturing clearance section of the checklist.
5. Update cleaning records and equipment logs accordingly.

5.3 Deviations During Line Clearance

1. Any discrepancy must be recorded in the Line Clearance Checklist and reported to QA.
2. Manufacturing activities must not commence unless clearance is formally approved.
3. In case of re-cleaning, repeat full clearance procedure and documentation.

5.4 Documentation

1. Maintain Line Clearance Checklists with batch records.
2. Store completed checklists for a minimum of one year post-expiry of batch.
3. Ensure traceability to specific equipment and area with date and time of clearance.

6. Abbreviations

• SOP: Standard Operating Procedure
• IPQA: In-Process Quality Assurance
• cGMP: Current Good Manufacturing Practices
• QA: Quality Assurance

7. Documents

1. Line Clearance Checklist (Annexure-1)
2. Cleaning Logbook
3. Equipment Usage Log

8. References

• 21 CFR Part 211.130 – Packaging and Labeling Control
• WHO GMP Guidelines for Pharmaceuticals
• EU GMP Annex 15 – Qualification and Validation

9. SOP Version

Version: 2.0

10. Approval Section

11. Annexures

Annexure-1: Line Clearance Checklist

Revision History:

Standard Operating Procedure for Destructive and Non-Destructive Testing of Elixir Products

1. Purpose

To establish a standardized procedure for distinguishing and conducting destructive and non-destructive tests on elixir formulations during in-process, finished product, and stability testing phases.

2. Scope

This SOP applies to the Quality Control Department and applies to all batches of elixirs where physical, chemical, or microbiological evaluations require either destructive or non-destructive approaches.

3. Responsibilities

• QC Analyst:
  • Perform assigned tests based on defined method classification (destructive/non-destructive).
• QC Supervisor:
  • Review test plans and ensure sample integrity based on test classification.
• QA Officer:
  • Review test execution strategy and approve method suitability.

4. Accountability

The QC Head is accountable for implementation and adherence to this SOP. The QA Head is responsible for ensuring that sample classification aligns with regulatory expectations and internal policies.

5. Procedure

5.1 Definitions

• Destructive Testing: Testing in which the sample is altered, destroyed, or rendered unusable post-evaluation.
• Non-Destructive Testing: Testing in which the sample remains intact and suitable for retention or further use.

5.2 Examples of Destructive Testing

• Assay of active ingredients by HPLC
• Preservative content and alcohol content tests
• Microbial limit testing
• pH testing requiring container opening

5.3 Examples of Non-Destructive Testing

• Visual inspection for clarity, color, and particulate matter
• Container integrity testing (e.g., vacuum leak detection, torque testing)
• Labeling, packaging, and fill volume inspection (external only)

5.4 Sample Management

1. Segregate samples for destructive vs. non-destructive tests before initiating testing.
2. Label containers appropriately with “Destructive” or “Non-Destructive”.
3. Record the batch number, container number, and purpose of test in the Sample Management Log (Annexure-1).

5.5 Testing and Reporting

1. Conduct tests as per the validated methods and document findings.
2. Destructive test samples must not be returned to inventory or reused.
3. Non-destructive test samples must be retained and handled per SOP for retained samples, if required.
4. Record results separately for each test type in respective data sheets or LIMS systems.

5.6 Disposal of Destructive Samples

1. Destroy samples post-testing in accordance with waste disposal SOP.
2. Document disposal details in the Sample Disposal Log with QA review.

5.7 Auditing and Review

1. QA shall review classification of test types periodically.
2. Any reclassification of a method must be updated in the master method list.

6. Abbreviations

• SOP: Standard Operating Procedure
• QC: Quality Control
• QA: Quality Assurance
• LIMS: Laboratory Information Management System

7. Documents

1. Sample Management Log (Annexure-1)
2. Sample Disposal Log
3. Master Test Method List

8. References

• ICH Q6A – Specifications: Test Procedures and Acceptance Criteria
• WHO Technical Report Series 996 – Annex 2
• 21 CFR Part 211 – Subpart I: Laboratory Controls

9. SOP Version

Version: 2.0

10. Approval Section

11. Annexures

Annexure-1: Sample Management Log

Revision History: